+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

R-CHOP is not effective regimen in CD5(+)DLBCL diagnosed by flow-cytometry/immunohistochemistry, karyotype and BCL2/BCL6 status and expression



R-CHOP is not effective regimen in CD5(+)DLBCL diagnosed by flow-cytometry/immunohistochemistry, karyotype and BCL2/BCL6 status and expression



Hematological Oncology 35: 333-334




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065040085

Download citation: RISBibTeXText

DOI: 10.1002/hon.2439_78


Related references

Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood 127(18): 2182-2188, 2016

BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. Blood 130(4): 489-500, 2017

MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?. Blood 121(12): 2165-2166, 2013

BCL2, p53 and Rb protein expression in activated lymphocytes Flow cytometry, static image analysis and immunohistochemistry in PHA-stimulated PBLS and microwave processed reactive tonsils. Pathology Research & Practice 189(6-7): 802-803, 1993

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica 98(2): 255-263, 2013

A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution. Oncotarget 7(27): 41242-41250, 2016

Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma. Ai Zheng 24(12): 1498-1502, 2005

Comparison between efficacy and safety of rituximab plus CHOP regimen and CHOP regimen for treatment of newly diagnosed patients with diffuse large B-cell lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16(4): 933-937, 2008

Bcl2-negative follicular lymphomas frequently have Bcl6 translocation and/or Bcl6 or p53 expression. Pathology International 57(3): 148-152, 2007

BCL2 in patients with non-Hodgkins lymphoma Correlations by flow cytometry, immunohistochemistry, and fluorescence in situ hybridization. Cytometry 42(5): 318-319, 2000

Flow-cytometry-based evaluation of peripheral blood lymphocytes in prognostication of newly diagnosed DLBCL patients. Blood Cells Molecules and Diseases 59: 92-96, 2016

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121(12): 2253-2263, 2013

Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 107(11): 4207-4213, 2006

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121(20): 4021-31; Quiz 4250, 2013

Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study (vol 107, pg 4207, 2006). Blood 109(6): 2292, 2007